Header Logo

Connection

MIMI I-NAN HU to Humans

Back to Details
This is a "connection" page, showing publications MIMI I-NAN HU has written about Humans.
MIMI I-NAN HU
Connection Strength
0.362
Humans
  1. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.
    View in: PubMed
    Score: 0.016
  2. Medullary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2021 10 01; 28(5):540-546.
    View in: PubMed
    Score: 0.016
  3. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab. 2021 07 13; 106(8):2198-2207.
    View in: PubMed
    Score: 0.016
  4. Adverse events associated with bone-directed therapies in patients with cancer. Bone. 2022 05; 158:115901.
    View in: PubMed
    Score: 0.015
  5. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocr Relat Cancer. 2020 08; 27(8):T27-T39.
    View in: PubMed
    Score: 0.015
  6. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019 02 01; 26(2):241-250.
    View in: PubMed
    Score: 0.013
  7. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015; 11(21):2865-71.
    View in: PubMed
    Score: 0.011
  8. Response letter to the editor. J Clin Endocrinol Metab. 2015 Jan; 100(1):L7.
    View in: PubMed
    Score: 0.010
  9. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014 Sep; 99(9):3144-52.
    View in: PubMed
    Score: 0.010
  10. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014 Jun; 43(2):423-42.
    View in: PubMed
    Score: 0.010
  11. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013 Sep 18; 105(18):1417-20.
    View in: PubMed
    Score: 0.009
  12. Medullary thyroid carcinoma: who's on first? Thyroid. 2012 May; 22(5):451-3.
    View in: PubMed
    Score: 0.008
  13. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol. 2011 May; 9(5):391-4.
    View in: PubMed
    Score: 0.008
  14. Medical management of postsurgical hypoparathyroidism. Endocr Pract. 2011 Mar-Apr; 17 Suppl 1:18-25.
    View in: PubMed
    Score: 0.008
  15. Cancer therapies and bone health. Curr Rheumatol Rep. 2010 Jun; 12(3):177-85.
    View in: PubMed
    Score: 0.007
  16. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):481-96, x-xi.
    View in: PubMed
    Score: 0.006
  17. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep. 2007 Dec; 5(4):170-8.
    View in: PubMed
    Score: 0.006
  18. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
    View in: PubMed
    Score: 0.005
  19. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
    View in: PubMed
    Score: 0.005
  20. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332.
    View in: PubMed
    Score: 0.005
  21. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024 Feb; 46(2):328-335.
    View in: PubMed
    Score: 0.005
  22. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.
    View in: PubMed
    Score: 0.005
  23. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne). 2023; 14:1176731.
    View in: PubMed
    Score: 0.005
  24. Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma. Thyroid. 2023 06; 33(6):774-776.
    View in: PubMed
    Score: 0.004
  25. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 02 15; 108(3):507-528.
    View in: PubMed
    Score: 0.004
  26. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.
    View in: PubMed
    Score: 0.004
  27. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep; 18(28):3143-3150.
    View in: PubMed
    Score: 0.004
  28. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
    View in: PubMed
    Score: 0.004
  29. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021 06 02; 28(7):419-431.
    View in: PubMed
    Score: 0.004
  30. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201.
    View in: PubMed
    Score: 0.004
  31. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.
    View in: PubMed
    Score: 0.004
  32. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799.
    View in: PubMed
    Score: 0.004
  33. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample. Cancer Cytopathol. 2020 07; 128(7):452-459.
    View in: PubMed
    Score: 0.004
  34. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
    View in: PubMed
    Score: 0.004
  35. Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. J Clin Ultrasound. 2020 May; 48(4):227-230.
    View in: PubMed
    Score: 0.004
  36. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
    View in: PubMed
    Score: 0.004
  37. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.003
  38. Vandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29.
    View in: PubMed
    Score: 0.003
  39. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.003
  40. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251.
    View in: PubMed
    Score: 0.003
  41. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018 09; 68(5):377-386.
    View in: PubMed
    Score: 0.003
  42. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
    View in: PubMed
    Score: 0.003
  43. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.003
  44. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018 Jan; 40(1):79-85.
    View in: PubMed
    Score: 0.003
  45. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
    View in: PubMed
    Score: 0.003
  46. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017 04; 16(2):283-289.
    View in: PubMed
    Score: 0.003
  47. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
    View in: PubMed
    Score: 0.003
  48. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.003
  49. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
    View in: PubMed
    Score: 0.003
  50. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76.
    View in: PubMed
    Score: 0.003
  51. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
    View in: PubMed
    Score: 0.003
  52. Thyroid Gland Malignancies. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1123-43.
    View in: PubMed
    Score: 0.003
  53. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90.
    View in: PubMed
    Score: 0.003
  54. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
    View in: PubMed
    Score: 0.003
  55. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
    View in: PubMed
    Score: 0.003
  56. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab. 2014 Dec; 99(12):4390-6.
    View in: PubMed
    Score: 0.003
  57. Vitamin D deficiency in mycosis fungoides and S?zary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):518-24.
    View in: PubMed
    Score: 0.003
  58. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.002
  59. Response. J Natl Cancer Inst. 2014 Jul; 106(7).
    View in: PubMed
    Score: 0.002
  60. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
    View in: PubMed
    Score: 0.002
  61. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May; 24(5):918-22.
    View in: PubMed
    Score: 0.002
  62. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.002
  63. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
    View in: PubMed
    Score: 0.002
  64. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):e398-400.
    View in: PubMed
    Score: 0.002
  65. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
    View in: PubMed
    Score: 0.002
  66. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg. 2012 Jun; 36(6):1320-6.
    View in: PubMed
    Score: 0.002
  67. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg. 2012 Apr; 147(4):338-44.
    View in: PubMed
    Score: 0.002
  68. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
    View in: PubMed
    Score: 0.002
  69. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011 Feb; 21(2):189-92.
    View in: PubMed
    Score: 0.002
  70. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011 Feb; 1218:47-54.
    View in: PubMed
    Score: 0.002
  71. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv. 2009 Jun; 3(2):75-88.
    View in: PubMed
    Score: 0.002
  72. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008 Jun; 23(6):826-36.
    View in: PubMed
    Score: 0.002
  73. Recent advances in thyroid cancer. In brief. Curr Probl Surg. 2008 Mar; 45(3):149-51.
    View in: PubMed
    Score: 0.002
  74. Recent advances in thyroid cancer. Curr Probl Surg. 2008 Mar; 45(3):156-250.
    View in: PubMed
    Score: 0.002
  75. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.